A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
RATIONALE:
Satraplatin is an oral platinum analog that is currently being evaluated in combination with
prednisone in a phase III clinical trial in patients with HRPC who have progressed following
one prior chemotherapy regimen.
Docetaxel is a taxane that is indicated for the treatment of patients with non-small cell
lung, breast, and prostate cancers. Specifically, it was recently approved in combination
with prednisone for the treatment of patients with hormone refractory prostate cancer
(HRPC). Docetaxel administered every 3 weeks was associated with a survival advantage versus
mitoxantrone. Docetaxel administered weekly showed an improvement in survival versus
mitoxantrone that was not statistically significant. However, it was better tolerated than
docetaxel administered every 3 weeks, with significantly less grade 3 and 4 toxicities,
especially neutropenia. The combination of satraplatin and weekly docetaxel may be a
feasible regimen for patients with chemotherapy-naïve HRPC and for patients with other
malignancies for which these medications show activity.
OBJECTIVE:
The objective of this study is to determine the optimum doses for satraplatin and weekly
docetaxel when the 2 drugs are given in combination.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the maximum tolerated dose (MTD) of satraplatin administered every 4 weeks in combination with docetaxel administered weekly (3 of 4 weeks)
30 days
Yes
Michael Petrone, MD
Study Director
GPC Biotech Inc.
United States: Food and Drug Administration
SAT1-05-09
NCT00313456
March 2006
March 2009
Name | Location |
---|---|
Sarah Cannon Research Institute | Nashville, Tennessee 37203 |